Tvardi Therapeutics, Inc. (TVRD)

Market Cap	265.29M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	9.36M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,222
Open	30.29
Previous Close	29.86
Day's Range	28.10 - 30.75
52-Week Range	8.13 - 34.31
Beta	n/a
Analysts	Strong Buy
Price Target	52.00 (+83.49%)
Earnings Date	May 13, 2025

About TVRD

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Su...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: TVRD
• Website: https://tvarditherapeutics.com

Analyst Forecast

According to 2 analysts, the average rating for TVRD stock is "Strong Buy." The 12-month stock price forecast is $52.0, which is an increase of 83.49% from the latest price.

Price Target

$52.0

(83.49% upside)

Analyst Consensus: Strong Buy